For R/M HNSCC, the overall survival (OS) is also prolonged by programmed cell death protein 1 (PD‐1) inhibitors in platinum‐refractory setting and first‐line setting compared with conventional systemic therapy3, 4, 5; however, negative results are found for the programmed death‐ligand 1 (PD‐L1) inhibitors and dual‐ICIs therapy.6, 7, 8. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.